Case Discussions: Prostate Cancer
|
|
- Britney Powell
- 6 years ago
- Views:
Transcription
1 Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic
2 Elevated PSA 1 54 yo, healthy male, family Hx of prostate cancer (father, age 64) CC: Rising PSA Negative TRUS/Bx x 3 (2006, 2008, 2009), including recent 28- core saturation biopsy under anesthesia (reviewed at CCF) No HG PIN, no ASAP in any biopsy specimen PSA history: DRE: normal TRUS volume: 23 cc (PSA Density 0.3) 03/ / / / (F:T 7%) (F:T 5%) 5.21
3 Elevated PSA 1 By PCPT risk calculator: Prostate cancer: 42% Biopsy Gleason 7-10: 8% though neg TRUS/Bx x 3! or Google PCPT risk calculator
4 Elevated PSA 1 Treatment options: FU with PSA In 1 year? In 4 years as per ERSPC? Urine PCA3 5-alpha reductase inhibitor as chemoprevention Finasteride? Dutasteride? Does it matter? Endorectal coil prostate MRI Repeat TRUS/Bx How many cores? Location?
5 Elevated PSA 1 Patient recommended to undergo repeat TRUS/Bx Standard 14-core medially- and laterally-directed biopsy of each sextant (12) and bilateral TZ biopsy Specific focus on apical biopsy
6 Elevated PSA 1 Sagittal Coronal SV Base Mid Apex R. L. Presti JC Jr. Urol Oncol 2009
7 Elevated PSA 1 Sagittal Coronal SV Base Mid Apex R. L. Presti JC Jr. Urol Oncol 2009
8 Elevated PSA 1 Left Right Base 0/1 HG PIN 0/1 0/1 0/1 Mid Apex 1/1+ Glsn % 1/1+ Glsn % 1/2+ (TZ+) Glsn % 0/1 HG PIN 0/2 0/1 0/1 0/1 Lateral Medial Medial Lateral
9 Elevated PSA 1 Nomogram predictions: 10-year PFP with radical prostatectomy: 93% Risk of extraprostatic extension: Left 16% 5-year PFP with EBRT: 93% 5-year PFP with brachytherapy: 82% Patient elected to undergo bilateral NS-RALRP Pathology: Organ-confined, Gleason 3+4, margins negative, volume > 2 cc, 14 negative lymph nodes 10-year PFP by nomogram: 93%
10 Elevated PSA 1 Issues: Balancing early detection with over-diagnosis Role of 5-alpha-reductase inhibitors Chemoprevention Enhancing early detection Improves AUC of PSA and DRE for prostate cancer diagnosis PSA response to 5-ARI to determine need for biopsy?
11
12 Prostate Cancer 1 65 y.o., healthy male CC: Localized prostate cancer PSA history: 03/ / / / / PSA velocity: 0.36 ng/ml/yr since 2001 DRE: normal 3/14 cores positive, Gleason 6 TRUS volume 40 cc; PSA density: 0.11
13 Prostate Cancer 1 Left Right Base Mid 1/1+ Gleason 6 < 5% 0/1 1/1+ Gleason 6 < 5% 0/1 0/1 1/1+ Gleason 6 < 5% 0/1 HG PIN 0/1 Apex 0/1 0/1 0/1 0/1 ASAP Lateral Medial Medial Lateral
14 Prostate Cancer 1 PMH: Hypertension, hypercholesterolemia PSH: appendectomy Parents both lived into late 80 s No family history of prostate Ca Potent, good erections high priority No voiding dysfunction
15 Prostate Cancer 1 Low-volume, Gleason 6 prostate cancer, T1C, low PSA Nomogram Outcome Predictions: 10-year PFP with radical prostatectomy: 98% 5-year PFP with EBRT (81 Gy): 95% 5-year PFP with brachytherapy: 90% Nomogram Pathology Predictions: ECE: Right 6%, Left 5% SVI and LNI: < 2% Indolent cancer: 46% Epstein criteria for indolent Ca met (T1C, Gleason 6, PSAD < 0.15, 3 or fewer cores involved, none > 50% cancer per core)
16 Prostate Cancer 1 What would you recommend this patient? Open radical prostatectomy Robotic or laparoscopic radical prostatectomy External-beam radiation therapy Brachytherapy Active surveillance Other (HIFU, cryotherapy, focal therapy) Other?
17 Prostate Cancer 1 Patient chooses active surveillance due to quality-of-life concerns Recommended repeat biopsy patient chooses to do this in 6 months after wintering in Florida
18 Prostate Cancer 1 Patient chooses active surveillance due to quality-of-life concerns Recommended repeat biopsy patient chooses to do this in 6 months after wintering in Florida How do you survey patients on active surveillance? Frequency of follow-up PSA testing Need for re-biopsy? How often? Other imaging modalities?
19 Prostate Cancer 1 Patient chooses active surveillance due to quality-of-life concerns Recommended repeat biopsy patient chooses to do this in 6 months after wintering in Florida How do you survey patients on active surveillance? Frequency of follow-up PSA testing Need for re-biopsy? How often? Other imaging modalities? By what criteria do you recommend treatment? PSA kinetics? Grade progression? Increasing cancer burden? Change in prognosis (e.g. nomogram)?
20 Prostate Cancer 1 Patient returns in 6 mos for FU PSA history: 03/ / / / / / / PSA velocity: 1.16 ng/ml/year DRE: normal Nomogram unchanged (indolent Ca, PFP w/ Rx) Very happy, not anxious, still sexually active
21 Prostate Cancer 1 Left Right 1/2+ 1/1+ 1/2+ 0/1 Base Glsn 3+4 Gleason 6 Gleason 6 ASAP 5% 5% < 5% Mid 1/1+ Gleason 6 1/1+ Glsn 3+4 1/2+ Gleason 6 1/1+ Gleason 6 40% 60% 20% 5% Apex 0/1 0/1 0/1 0/1 Lateral Medial Medial Lateral
22 Prostate Cancer 1 7/17 cores positive, Gleason 3+4, T1c, PSA 5.3 Prognosis: Radical prostatectomy: 10-year PFP 84% EBRT: 5-year PFP 93% Brachytherapy: 5-year PFP 82% Pathological Staging: ECE: Right 6%, Left 9%
23 Prostate Cancer 1 What would you recommend this patient? Open radical prostatectomy Robotic or laparoscopic radical prostatectomy External-beam radiation therapy Brachytherapy Continued active surveillance Other (HIFU, cryotherapy, focal therapy) Other?
24 Prostate Cancer 1 Patient elected to undergo bilateral NS-RRP Final pathology: Established extraprostatic extension (bilateral), Gleason 3+4, negative margins, volume cc, 12 negative LN 10-year PFP by nomogram: 73% 8 wks postop: pad-free, erections adequate for intercourse with PDE5i, PSA NMA
25 Prostate Cancer 1 pt3a, Gleason 3+4, SM negative, PSA NMA Next step: Observation Adjuvant Radiotherapy Adjuvant ADT Observation and salvage radiotherapy at BCR Observation and ADT at BCR Other
26 Prostate Cancer 1 pt3a, Gleason 3+4, SM negative, PSA NMA Next step: Observation Adjuvant Radiotherapy Adjuvant ADT Observation and salvage radiotherapy at BCR Observation and ADT at BCR Other What if positive surgical margin?
27 Prostate Cancer 1 pt3a, Gleason 3+4, SM negative, PSA NMA Next step: Observation Adjuvant Radiotherapy Adjuvant ADT Observation and salvage radiotherapy at BCR Observation and ADT at BCR Other What if seminal vesicle invasion?
28 Prostate Cancer 1 pt3a, Gleason 3+4, SM negative, PSA NMA Next step: Observation Adjuvant Radiotherapy Adjuvant ADT Observation and salvage radiotherapy at BCR Observation and ADT at BCR Other What if detectable PSA level postop?
29 Prostate Cancer 1 Patient elected observation 2009: PSA NMA; continent, potent
30
31 Prostate Cancer 2 53 y.o. healthy male CC: Prostate cancer PSA history: 11/ / / / PSA velocity: 3.0 ng/ml/year DRE: nodules bilaterally, EPE+ (R. mid-base) Gleason 8, 12/12 cores positive, PNI+
32 Prostate Cancer 2 Left Right 1/1+ 1/1+ 1/1+ 1/1+ Base Glsn 4+3 Gleason 8 Glsn 3+4 Glsn % 80%, PNI+ 80%, PNI+ 100%, PNI+ Mid 1/1+ Gleason 8 1/1+ Glsn 4+3 1/1+ Glsn 3+4 1/1+ Glsn %, PNI+ 95%, PNI+ 60% 80%, PNI+ Apex 1/1+ Glsn 4+3 1/1+ Glsn 4+3 1/1+ Glsn 3+4 1/1+ Glsn % 95% 50% 90% Lateral Medial Medial Lateral
33 Prostate Cancer 2 PMH: none PSH: none Family history: no prostate Ca, both parents alive 75 and 83 yrs Erections slightly diminished (not sexually active) No voiding dysfunction
34 Prostate Cancer 2 Bone scan: No mets CT AP WWO contrast: 2.2 x 0.9 left external iliac node 1.6 x 0.7 right external iliac node Prognosis: RRP: 5-year PFP 28% EBRT (+ ADT): 5-year PFP 46% Pathology: ECE: Left 93%, Right 93% SVI: 72% LNI: 56%
35 Prostate Cancer 2 T3a, Gleason 8, PSA 27.6 ng/ml, clinically LN+, M0 Treatment options: Lymph node biopsy Open or laparoscopic radical prostatectomy Neoadjuvant ADT followed by RP EBRT + 6 mos ADT EBRT yrs ADT ADT as primary therapy Enroll in clinical trial neoadjuvant docetaxel + ADT Radical prostatectomy (CALGB - PUNCH) EBRT (RTOG)
36 Prostate Cancer 2 Patient opted for open radical prostatectomy Bilateral nerve resection Pathology: Bilateral established extraprostatic extension Left SVI Gleason 4+3 Negative margins 3 of 18 positive nodes (bilateral) 10-year PFP by nomogram: 12%
37 Prostate Cancer 2 6 weeks postop: PSA 0.11 ng/ml No erections, 1 pad daily for incontinence Treatment options: Immediate EBRT Immediate ADT Immediate chemotherapy and ADT Observation with salvage EBRT at PSA relapse Observation with salvage ADT at PSA relapse (use PSA DT) Observation with salvage ADT at clinical progression
38 Prostate Cancer 2 Elected to follow patient close with plan for deferred ADT based on PSA level and PSA DT PSA history: 05/ / /2007 PSA doubling time: < 3 months months postop: started on ADT (LHRH agonist + AA) Continuous vs. intermittent? Need for bone densitometry? Calcium + vitd3 supplementation? Assess cardiac risk factors? Fasting glucose? Lipid profile?
39 Prostate Cancer 2 Started on intermittent ADT continue if nadir PSA < ADT Start 16 PSA level, ng/ml ADT Start ADT Stop ADT Stop ADT Stop Ser i es Months from Radical Prostatectomy
40 Prostate Cancer-Specific Mortality after Radical Prostatectomy Gleason 8-10 Seminal Vesicle Invasion Lymph Node Metastasis PCSM by Specimen Gleason Score PCSM by Pathologic Stage Stephenson et al. ASCO 2009
41
42 Prostate Cancer 3 53 y.o. healthy male CC: Localized prostate cancer PSA history: 04/ / / / PSA velocity: 3.32 ng/ml/year DRE: Nodule R. mid, T2a Gleason 8, 4/12 cores positive
43 Prostate Cancer 3 Left Right 0/1 1/1+ 0/1 0/1 Base ASAP Glsn 3+4 HG PIN HG PIN 25% Mid 0/1 HG PIN 1/1+ Gleason 8 1/1+ Gleason 8 0/1 HG PIN 10% 50% Apex 1/1+ Gleason 6 0/1 HG PIN 0/1 0/1 10% Lateral Medial Medial Lateral
44 Prostate Cancer 2 PMH: none PSH: none Family history: none Erections Normal (sexually active) No voiding dysfunction
45 Prostate Cancer 3 Bone scan: No mets CT AP WWO contrast: No mets Prognosis: RRP: 10-year PFP 81% EBRT (+ ADT): 5-year PFP 79% Pathology: Organ-confined: 46% ECE: 45% SVI: 30% LNI: 9%
46 Prostate Cancer 3 Standard options discussed for high-risk cancer Erections very important but wants to be cured Treatment options: External-beam radiotherapy +/- ADT Radical prostatectomy Nerve-sparing? Unilateral? Bilateral? Partial vs. complete resection? Decision-making?
47 Cancer Control: Positive Surgical Margins Open RP No. Pts pt2 pt3 Touijer et al % 22% Harris % 48% Smith et al % 60% Han et al % 23% RALRP or LRP* Menon et al % 35% Patel et al % 35% Smith et al % 50% Zorn et al % 48% Touijer et al. 2006* 485 8% 17%
48 Positive Surgical Margins Surgeon is independent predictor of SM+ SM+ risk of PSA recurrence by 2-4 fold Eastham et al. J Urol 2003 Swindle et al. J Urol 2005; Stephenson et al. J Urol 2009 SM+ are frequent indicator for secondary therapy Van der Kwast et al. J Clin Oncol 2008 SM+ may risk of PCSM (HR 1.14, P < 0.001) Stephenson et al. ASCO 2009
49 Side-Specific Risk of Extraprostatic Extension Ohori et al. J Urol 2004;
50 Prostate Cancer 3 Bone scan: No mets CT AP WWO contrast: No mets Prognosis: RRP: 10-year PFP 81% EBRT (+ ADT): 5-year PFP 79% Pathology: ECE: Left 30%, Right 23% SVI: 30% LNI: 9%
51 Prostate Cancer 3 Patient elected to undergo RALRP Bilateral nerve-sparing Pathology: pt2, Gleason 4+3, SM negative, 0/14 LN+ Follow-up: 6 months postop PSA NMA Continent Sexually active with PDE-5 inhibitor
52
Detection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationS Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet
S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet Why HIFU? Efficacy demonstrated Real time control of the target Early control of the necrosis area is possible with MRI or TRUS using contrast
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationProstatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London
Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationProstate MRI for local staging and surgical planning in prostate cancer
Prostate MRI for local staging and surgical planning in prostate cancer 15th Annual Floyd A. Fried Advances in Urology Symposium June 23, 2017 Ray Tan, MD, MSHPM Assistant Professor Disclosures None Objectives
More informationProstate Cancer Innovations in Surgical Strategies Update 2007!
Prostate Cancer Innovations in Surgical Strategies Update 2007! Curtis A. Pettaway, M.D. Professor Department of Urology The University of Texas M. D. Anderson Cancer Center Radical Prostatectomy Pathologic
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationLow risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer
Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationProstate Cancer- Screening and Selected Treatment Dilemmas COPYRIGHT. Marc B. Garnick MD. Update in Internal Medicine.
Prostate Cancer- Screening and Selected Treatment Dilemmas Marc B. Garnick MD Update in Internal Medicine 4 December 2016 Financial Disclosures Marc B. Garnick MD, FACP Gorman Brothers Clinical Professor
More informationACTIVE SURVEILLANCE FOR PROSTATE CANCER
ACTIVE SURVEILLANCE FOR PROSTATE CANCER Dr. Michael J Metcalfe PGY-2 Department of Urological Sciences April 25, 2012 CASE RM 65 year old active Caucasian male, married. PSA= 7.0 T2a Gleason 3+3=6 2/6
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationda Vinci Prostatectomy
da Vinci Prostatectomy Justin T. Lee MD Director of Robotic Surgery Urology Associates of North Texas (UANT) USMD Prostate Cancer Center (www.usmdpcc.com) Prostate Cancer Facts Prostate cancer Leading
More informationHow to deal with patients who fail intracavitary treatment
How to deal with patients who fail intracavitary treatment A. Heidenreich Department of Urology Non-surgical therapy of PCA IMRT SEEDS IGRT HDR-BRACHY HIFU CRYO LDR - Brachytherapy Author Follow-up bned
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationCase #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).
SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationTrends in Prostate Cancer Bob Weir AVP Underwriting Research Canada Life Reinsurance
Trends in Prostate Cancer Bob Weir AVP Underwriting Research Canada Life Reinsurance Metropolitan Underwriting Discussion Group Annual Meeting January 30, 2017 Prostate Cancer is Common Rudy Giuliani Dx
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationHigh Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November D. Maruzzi - L. Ruggera
High Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November 2014 D. Maruzzi - L. Ruggera HIFU development Second prototype 1995-2000 Integrated Imaging 2006-2010 1993
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationFocal Therapy is a Fool s Paradise : The whole prostate must be treated!
Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Ofer Yossepowitch, MD Head, Department of Urology Tel Aviv Sourasky Medical Center Preaching against focal therapy in a focal therapy
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationRationale for Multimodality Therapy for High Risk Localized Prostate Cancer
Rationale for Multimodality Therapy for High Risk Localized Prostate Cancer 100 80 60 Cancer Death Rates for Men, US 1930-2002 Rate Per 100,000 Lung William K. Oh, M.D. 40 Stomach Colon & rectum Prostate
More informationSalvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK
Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option
More informationPSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016
PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence
More informationOpen Prostatectomy is Best
Open Prostatectomy is Best William J. Catalona, M.D. The Trifecta Trifecta Cure Continence Potency Northwestern University Feinberg School of Medicine Eastham, J et al, JUrol 179:2207 Continence (Pad Free
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationDate Modified: May 29, Clinical Quality Measures for PQRS
Date Modified: May 29, 2014 Clinical Quality s for PQRS # Domain Type Denominator Numerator Denominator Exclusions/Exceptions Rationale QCDR-1 QCDR-2 Patient Safety 102 Efficiency and Cost Reduction QCDR-3
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationDepartment of Urology, Cochin hospital Paris Descartes University
Technical advances in the treatment of localized prostate cancer Pr Michaël Peyromaure Department of Urology, Cochin hospital Paris Descartes University Introduction Curative treatments of localized prostate
More informationProstate Cancer UK s Best Practice Pathway
Prostate Cancer UK s Best Practice Pathway TREATMENT Updated August 2018 To be updated in vember Active surveillance What is the patient s stage of disease? Low risk localised PSA < 10 ng/ml and Gleason
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationMen s Health Topics. Jerome Baca, MS, PA-C. Albuquerque Urology Associates January 6 th, 2018
Men s Health Topics Jerome Baca, MS, PA-C Albuquerque Urology Associates January 6 th, 2018 1 ns 2 Prostate Cancer (pca) Most common type of cancer in men 45-75yo > 95% is adenocarcinoma: CA arising from
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationCase Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.
Case Scenario 1 3/8/13 H&P 68 YR W/M presents w/elevated PSA. Patient is a non-smoker, current alcohol use. Physical Exam: On digital rectal exam the sphincter tone is normal and there is a 1 cm nodule
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationCytoreductive Radical Prostatectomy for de Novo Metastatic Prostate Cancer
Cytoreductive Radical Prostatectomy for de Novo Metastatic Prostate Cancer Timothy G. Wilson, MD Professor and Chair of Urology John Wayne Cancer Institute Santa Monica, California Disclosures I am on
More informationProstate Cancer. David Wilkinson MD Gulfshore Urology
Prostate Cancer David Wilkinson MD Gulfshore Urology What is the Prostate? Male Sexual Gland Adds nutrients and fluids for sperm This fluid is added to sperm during ejaculation Urethra (urine channel)
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationNeoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationProstate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE
Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason
More informationDate Modified: March 31, Clinical Quality Measures for PQRS
Date Modified: March 31, 2015 2015 Clinical Quality s for PQRS # Domain Title Description Type Denominator Numerator Denominator Exclusions/Exceptions 1 Patient Safety Prostate Biopsy Antibiotic Process
More informationProstate Cancer Case Study 1. Medical Student Case-Based Learning
Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You
More informationARRO-Case Postoperative Radiotherapy in Prostate Cancer
ARRO-Case Postoperative Radiotherapy in Prostate Cancer Kara Downs Romano, Daniel Trifiletti, Timothy Showalter Radiation Oncology University of Virginia Charlottesville, VA Case: HPI 64 year old man with
More informationState-of-the-art: vision on the future. Urology
State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures
More informationPORT after RP. Adjuvant. Salvage
PORT after RP Adjuvant Or Salvage RT after RP 40-50% PSA relapse after RP in HR Definition: PSA should be undetectable within 6 weeks of RP Initial PSA is measured 6-12 weeks after RP AUA defines biochemical
More information18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan
An update for GPs on modern radiation therapy & hormones for prostate cancer A/Prof Jeremy Millar Director Radiation Oncology, Alfred Health Clinical lead Prostate Cancer Outcomes Registry, Monash University
More informationUtility of Prostate MRI. John R. Leyendecker, MD
Utility of Prostate MRI John R. Leyendecker, MD Professor of Radiology and Urology Executive Vice Chair of Clinical Operations Section Head, Abdominal Imaging Wake Forest University School of Medicine;
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationComparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy
Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy By: Jonathan Barlaan; Huy Nguyen Mentor: Julio Powsang, MD Reader: Richard Wilder, MD May 2, 211 Abstract Introduction: The
More informationPROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging
PROSTATE MRI Dr. Margaret Gallegos Radiologist Santa Fe Imaging Topics of today s talk How does prostate MRI work? Definition of multiparametric (mp) MRI Anatomy of prostate gland and MRI imaging Role
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationNavigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News
Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools
More informationFinancial Disclosures. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Financial Disclosures
More informationManaging Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?
Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Michael J Zelefsky, M.D. Professor of Radiation Oncology Chief Brachytherapy Service Department of Radiation Oncology
More informationInception Cohort. Center for Evidence-Based Medicine, Oxford VIP-- Inception Cohort (2008) Nov Dec
VIP-- Inception Cohort (28) Robotic Prostatectomy: Oncological and Functional Outcomes after 4 cases The Donald Smith Lecture Nov 2- Dec 28---- ----42 patients Patient 1 to patient 38 PSA follow-up -------3481
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationIn autopsy, 70% of men >80yr have occult prostate ca
Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease
More informationAnatomic Imaging of Prostate Cancer
Masoom Haider, MD, FRCP(C) Professor of Radiology, University of Toronto Clinician Scientist, Ontario Institute of Cancer Research Senior Scientist, Sunnybrook Research Institute Chief, Dept of Medical
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationDavid Gillatt Bristol Urological Institute. David Gillatt Bristol UK
David Gillatt Bristol Urological Institute David Gillatt Bristol UK Prostate Problems The prostate grows with age - >80% men over 60 have benign enlargement As it grows it can obstruct the flow of urine
More informationPROSTATE CANCER: A Primer of Diagnosis and Treatment. Jay C. Lee, MD, FRCSC Clinical Associate Professor University of Calgary
PROSTATE CANCER: A Primer of Diagnosis and Treatment Jay C. Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationProstate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018
Prostate cancer staging and datasets: The Nitty-Gritty What determines our pathological reports? Dan Berney Maastricht 2018 Biopsy reporting. How not to do it. The TNM 8 th edition. Changes good and bad
More informationClinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease Jeffrey A. Cadeddu, MD Professor, Department of Urology UT Southwestern Medical Center Vice-Chair, AUA/ASTRO/SUO
More information5. Localised prostate cancer
5. Localised prostate cancer From an anatamopathological point of view, localised prostate cancer is the verified presence of prostate adenocarcinoma without extension to the prostate capsule (pt1-pt2),
More informationIN RADIOTERAPIA BEST PAPERS. Direttore Unità Operativa Complessa Radioterapia Oncologica
IN RADIOTERAPIA BEST PAPERS 2014 FILIPPO ALONGI Direttore Unità Operativa Complessa Radioterapia Oncologica PROSTATE RT: WHERE WE ARE GOING? RT has evolved from radium(1911) to high Technology and high
More informationErectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer. William M. Mendenhall, MD
Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer William M. Mendenhall, MD Meta-Analysis of Probability of Maintaining Erectile Function after Treatment of Localized Cancer Treatment
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationEORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
More informationThe Role of Adjuvant vs Salvage Radiation Therapy after Prostatectomy. Dr. Matt Andrews Supervisor: Dr. David Bowes
The Role of Adjuvant vs Salvage Radiation Therapy after Prostatectomy Dr. Matt Andrews Supervisor: Dr. David Bowes Objectives Discuss the evidence for adjuvant radiotherapy (ART) EORTC, SWOG, ARO Current
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationProstate Cancer Grading, Staging and Reporting: An Update Cristina Magi-Galluzzi, MD, PhD
Prostate Cancer Grading, Staging and Reporting: An Update Cristina Magi-Galluzzi, MD, PhD Director, Genitourinary Pathology R.J. Tomsich Pathology & Laboratory Medicine Institute Professor of Pathology,
More information10/30/2018. Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018
Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018 Elevated PSA and/or nodule on digital rectal examination Prostate biopsies If initial
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More informationEVIDENCE SUPPORTING TESTOSTERONE THERAPY IN MEN WITH PROSTATE CANCER
EVIDENCE SUPPORTING TESTOSTERONE THERAPY IN MEN WITH PROSTATE CANCER Abraham Morgentaler, MD Director and Founder Men s Health Boston Associate Clinical Professor Harvard Medical School And the Urology
More informationPatterns of care for prostate cancer An update
Patterns of care for prostate cancer An update Daniel Moon Director of Robotic Surgery Epworth Healthcare Honorary Clinical Senior Lecturer University of Melbourne Consultant Urologist Peter MacCallum
More informationChapter 2. Understanding My Diagnosis
Chapter 2. Understanding My Diagnosis With contributions from Nancy L. Brown, Ph.D.,Palo Alto Medical Foundation Research Institute; and Patrick Swift, M.D., Alta Bates Comprehensive Cancer Program o Facts
More information16:30-18:30 WS #67: Urology Forum - Prostate Cancer, Stones, Renal Tumours, Voiding Dysfunction (120 minutes, not repeated) -
Dr Anna Lawrence Urologist Auckland Dr Andrew Williams Urologist Auckland Madhu Koya Urologist Auckland Andrew Lienert Urologist Auckland Dr Louise Tomlinson Consultant Gynaecologist Auckland 16:30-18:30
More informationD. Jeffrey Demanes M.D. FACRO, FACR, FASTRO Director UCLA Brachytherapy combined HDR + EBRT 574 HDR monotherapy Total Patients
Salvage Prostate Brachytherapy D. Jeffrey Demanes M.D. FACRO, FACR, FASTRO Director UCLA Brachytherapy 1996-2013 1515 combined HDR + EBRT 574 HDR monotherapy 36 Salvage 2125 Total Patients No Disclosure
More informationBiochemical recurrence rate in patients with positive surgical margins at radical prostatectomy with further negative resected tissue
. JOURNAL COMPILATION 2009 BJU INTERNATIONAL Urological Oncology BIOCHEMICAL RECURRENCE RATE WITH POSITIVE SURGICAL MARGINS AT RP WITH NEGATIVE RESECTED TISSUE RABBANI et al. BJUI BJU INTERNATIONAL Biochemical
More informationProstate Cancer Dashboard
Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More information